NEW YORK (GenomeWeb) – Novogene and Pacific Biosciences said today that they plan to co-develop and co-market applications based on PacBio’s Sequel system that focus on basic and translational research in precision medicine.
In particular, the firms will focus on methods for sample processing, workflow automation, algorithm development, and database construction.
Financial and other details of the agreement were not disclosed.
Novogene is a sequencing service provider based in Beijing, but also has branches in Hong Kong, the US, and the UK. It operates 10 Sequel systems and has expertise in developing sample preparation, data analysis, and interpretation tools.